- Home
- TXO vs EMBC Comparison
TXO vs EMBC Comparison
Compare TXO & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- EMBC
- Stock Information
- Founded
- TXO 2012
- EMBC 1924
- Country
- TXO United States
- EMBC United States
- Employees
- TXO N/A
- EMBC N/A
- Industry
- TXO Oil & Gas Production
- EMBC Medical/Dental Instruments
- Sector
- TXO Energy
- EMBC Health Care
- Exchange
- TXO Nasdaq
- EMBC Nasdaq
- Market Cap
- TXO 788.9M
- EMBC 788.4M
- IPO Year
- TXO 2023
- EMBC N/A
- Fundamental
- Price
- TXO $14.01
- EMBC $15.06
- Analyst Decision
- TXO Strong Buy
- EMBC Buy
- Analyst Count
- TXO 2
- EMBC 2
- Target Price
- TXO $21.50
- EMBC $18.50
- AVG Volume (30 Days)
- TXO 145.0K
- EMBC 488.5K
- Earning Date
- TXO 11-04-2025
- EMBC 08-08-2025
- Dividend Yield
- TXO 17.10%
- EMBC 3.96%
- EPS Growth
- TXO N/A
- EMBC 18.26
- EPS
- TXO 0.30
- EMBC 1.42
- Revenue
- TXO $332,267,000.00
- EMBC $1,102,500,000.00
- Revenue This Year
- TXO $31.08
- EMBC N/A
- Revenue Next Year
- TXO $11.32
- EMBC N/A
- P/E Ratio
- TXO $47.41
- EMBC $10.67
- Revenue Growth
- TXO 15.94
- EMBC N/A
- 52 Week Low
- TXO $13.28
- EMBC $9.20
- 52 Week High
- TXO $20.70
- EMBC $21.48
- Technical
- Relative Strength Index (RSI)
- TXO 49.14
- EMBC 64.69
- Support Level
- TXO $13.42
- EMBC $14.92
- Resistance Level
- TXO $13.88
- EMBC $15.44
- Average True Range (ATR)
- TXO 0.29
- EMBC 0.52
- MACD
- TXO 0.07
- EMBC -0.09
- Stochastic Oscillator
- TXO 79.89
- EMBC 66.67
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.